American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting (AAAAI 2022)

Anaphylaxis after COVID mRNA vaccination relatively rare

Roshini Claire Anthony, 20220406180001

Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.

Benralizumab reduces asthma exacerbation rates in real-world setting

Elaine Soliven, 20220331000000

Treatment with benralizumab significantly reduces exacerbation rates in patients with asthma in a real-world setting, according to the ZEPHYR 2 study presented at AAAAI 2022.

Tezepelumab cuts asthma attacks in patients with severe asthma across seasons

Pearl Toh, 20220330140100

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.

Abrocitinib effectively manages AD flares

Audrey Abella, 20220321100000

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

COVID-19 vax tolerated even in people with mast cell activation syndrome

Pearl Toh, 20220318140100

COVID-19 vaccination is generally well tolerated, even in people with mast cell activation syndrome (MCAS) —among whom vaccine hesitancy is high, according to studies presented at AAAAI 2022.

Budesonide reduces nasal congestion symptoms in adults with rhinitis

Elaine Soliven, 20220317000000

Treatment with intranasal budesonide significantly reduces nasal congestion symptoms in adults with rhinitis triggered or worsened by airborne pollution, according to a study presented at AAAAI 2022.

EMPOWER reflects efficacy, safety of lanadelumab for HAE in real world

Audrey Abella, 20220307100000

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).

Ligelizumab improves symptoms, QoL in patients with urticaria

Audrey Abella, 20220302100000

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.